Remove Hospitals Remove Immune Response Remove Vaccine
article thumbnail

Sanofi Speeds Up Beyfortus Shipments Ahead of 2025-2026 RSV Season

The Pharma Data

According to Thomas Triomphe, Executive Vice President of Vaccines at Sanofi, the product has been administered to over 250,000 infants in real-world settings, backed by more than 40 studies demonstrating its effectiveness in preventing RSV lower respiratory tract disease.

Virus 40
article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

According to the FDA, these REMS requirements are no longer necessary to ensure safe use of these CAR-T therapies as both physicians and hospitals are now well versed in managing the two syndromes most commonly associated with the drugs. appointed panel recommends flu shots be free of contested preservative CDC panel, newly remade by RFK Jr.,

Therapies 178
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Ongoing Challenges of Understanding Long COVID and Exploring Innovative Solutions

Perficient: Drug Development

This pattern may relate to differences in immune response, organ-specific vulnerability, or patterns of healthcare utilization. Differential Immune Response: Women with Long COVID typically show higher levels of IL-6 compared to men, particularly those with central sensitization phenotypes.

article thumbnail

Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response

The Pharma Data

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

article thumbnail

Covid vaccine: Trial of new coronavirus vaccine starts in UK

The Pharma Data

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. The trial on 10,000 people will now see if the vaccine can prevent people getting ill. A vaccine that can protect people from Covid-19 is still widely seen as the main exit strategy from the restrictions on all our lives.

Vaccine 52
article thumbnail

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate

The Pharma Data

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.

article thumbnail

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine

The Pharma Data

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “